Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants.

Alimohammadi E, Bagheri SR, Salehi AS, Rizevandi P, Rezaie Z, Abdi A.

Acta Neurol Belg. 2019 Jun 20. doi: 10.1007/s13760-019-01171-x. [Epub ahead of print]

PMID:
31222512
2.

Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience.

Guden M, Ayata HB, Ceylan C, Kilic A, Engin K.

Indian J Cancer. 2016 Jul-Sep;53(3):382-386. doi: 10.4103/0019-509X.200664.

3.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
4.

Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfini R.

Tumori. 2007 May-Jun;93(3):248-56.

PMID:
17679459
5.

The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.

Rapp M, Goeppert M, Felsberg J, Steiger HJ, Sabel M.

Br J Neurosurg. 2013 Aug;27(4):430-5. doi: 10.3109/02688697.2013.767317. Epub 2013 Feb 18.

PMID:
23418781
6.

Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.

Evers PD, Logan JE, Sills V, Chin AI.

World J Urol. 2014 Apr;32(2):385-91. doi: 10.1007/s00345-013-1110-7. Epub 2013 Jun 12.

PMID:
23756991
7.

Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M.

J Neurosurg Sci. 2010 Mar;54(1):7-19.

PMID:
20436394
8.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
9.

Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute.

Turkoglu E, Gurer B, Sanli AM, Dolgun H, Gurses L, Oral NA, Donmez T, Sekerci Z.

Clin Neurol Neurosurg. 2013 Dec;115(12):2508-13. doi: 10.1016/j.clineuro.2013.10.010. Epub 2013 Oct 25.

PMID:
24225484
10.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

11.

Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score-matching analysis.

Liu YL, Liu PF, Shao W, Du HP, Li ZZ, Guo C, Li ZF.

Onco Targets Ther. 2017 Aug 14;10:4029-4035. doi: 10.2147/OTT.S123473. eCollection 2017. Erratum in: Onco Targets Ther. 2017 Sep 18;10 :4615.

12.

Cerebellar glioblastoma: a retrospective review of 21 patients at a single institution.

Tsung AJ, Prabhu SS, Lei X, Chern JJ, Benjamin Bekele N, Shonka NA.

J Neurooncol. 2011 Dec;105(3):555-62. doi: 10.1007/s11060-011-0617-2. Epub 2011 Jun 4. Review.

PMID:
21643841
13.

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.

Toms SA, Kim CY, Nicholas G, Ram Z.

J Neurooncol. 2019 Jan;141(2):467-473. doi: 10.1007/s11060-018-03057-z. Epub 2018 Dec 1.

14.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

15.

Radiotherapy with and without temozolomide in elderly patients with glioblastoma.

Niyazi M, Schwarz SB, Suchorska B, Belka C.

Strahlenther Onkol. 2012 Feb;188(2):154-9. doi: 10.1007/s00066-011-0026-7. Epub 2012 Jan 11.

PMID:
22231634
16.

Primary glioblastoma multiforme in younger patients: a single-institution experience.

Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M.

Tumori. 2006 Sep-Oct;92(5):407-11.

PMID:
17168433
17.

Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.

Lukács G, Tóth Z, Sipos D, Csima M, Hadjiev J, Bajzik G, Cselik Z, Semjén D, Repa I, Kovács Á.

Ideggyogy Sz. 2018 Mar 30;71(3-04):95-103. doi: 10.18071/isz.71.0095.

PMID:
29889468
18.

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.

Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M.

Neurology. 2017 Apr 11;88(15):1422-1430. doi: 10.1212/WNL.0000000000003809. Epub 2017 Mar 15.

19.

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.

Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM.

J Neurooncol. 2018 May;138(1):155-162. doi: 10.1007/s11060-018-2782-z. Epub 2018 Feb 1.

PMID:
29388034
20.

Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors.

Hollon T, Nguyen V, Smith BW, Lewis S, Junck L, Orringer DA.

J Neurosurg. 2016 Aug;125(2):410-8. doi: 10.3171/2015.7.JNS151187. Epub 2016 Jan 8. Review.

PMID:
26745489

Supplemental Content

Support Center